| Drug therapy |
|
|
|
|
| Antiviral agents, n (%) | 98 (100) | 76 (100) | 22 (100) | 1.0 |
| rIFNα2b, n (%) | 98 (100) | 76 (100) | 22 (100) | 1.0 |
| Glucocorticoids, n (%) | 21 (21.4) | 4 (5.3) | 17 (77.3) | 0.000 |
| Immunoglobulin, n (%) | 16 (16.3) | 2 (2.6) | 14 (63.6) | 0.000 |
| Vitamin C, n (%) | 24 (24.5) | 17 (22.4) | 7 (31.2) | 0.36 |
| Antibacterial agents, n (%) | 32 (32.7) | 20 (26.3) | 12 (54.5) | 0.013 |
| Onset of symptom to Hospital admission, median (IQR), d | 6.0 (5.0) | 5.0 (5.0) | 6.5 (7.8) | 0.40 |
| HLOS, median (IQR), d | 15.6 (11.0) | 13.0 (11.0) | 20.5 (8.5) | 0.001 |
| Clinic course, median (IQR), d | 21.7 (9) | 19.5 (8.8) | 26.5 (14.3) | 0.000 |